Selected Publications Silvia Marsoni

Highlights

1. Siena S, Marsoni S, Sartore-Bianchi A.
   Breaking Barriers in HER2+ Cancers.
   Cancer Cell. 2020 Sep 14;38(3):317-319. doi: 10.1016/j.ccell.2020.07.012. Epub 2020 Aug 27. PMID: 32857948.


2. Sara Lonardi, Clara Montagut, Filippo Pietrantonio, Elena Elez, Andrea Sartore-Bianchi, Noelia Tarazona, Stefania Sciallero, M. Giolia Zampino, Stefania Mosconi, Susana Muñoz, Luca Lazzari, Paolo Luraghi, Salvatore Siena, Alberto F. Sobrero, Roberto Labianca, Valter Torri, Alberto Bardelli, Josep Tabernero, and Silvia Marsoni.
   The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients.
   Journal of Clinical Oncology 2020 38:15_suppl, TPS4124-TPS4124


3. Paolo Luraghi, Luca Lazzari, Maria Vittoria Dieci, Serena Bellani, Chiara Soffientini, Rosario Rizzuto, Antonio Rosato, Vincenzo Costanzo, Giorgio Scita, Giannino Del Sal, Massimiliano Pagani, Marco Foiani, Claudio Tripodo, Silvio Bicciato, Giovanni Blandino, Alberto Zambelli, Valter Torri, Matteo Fassan, PierFranco Conte, Silvia Marsoni, Stefano Piccolo.
   METAMECH - A Master Observational Trial empowering mechanobiology translational research and mechanobased proof of concept trials in breast cancer
   Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr CT261.


4. Siravegna G, Sartore-Bianchi A, Nagy RJ, Raghav K, Odegaard JI, Lanman RB, Trusolino L, Marsoni S, Siena S, Bardelli A.
   Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer.
   Clin Cancer Res. 2019 May 15;25(10):3046-3053. doi: 10.1158/1078-0432.CCR-18-3389. Epub 2019 Feb 26. PMID: 30808777.


5. Luca Lazzari, Paolo Luraghi, Nabil Amirouchene-Angelozzi, Andrea Bertotti, Enzo Medico, Federica Di Nicolantonio, Fabrizio d'Adda di Fagagna, Sergio Abrignani, Daniele Regge, Anna Sapino, Emanuela Bonoldi, Angelo Vanzolli, Vittorina Zagonel, Filippo de Braud, Livio Trusolino, Alberto Bardelli, Salvatore Siena, Silvia Marsoni.
   AlfaOmega - a master protocol empowering precision research in colorectal cancer
   Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT214.


6. Salvatore Siena, Andrea Sartore-Bianchi, Nicola Personeni, Filippo Pietrantonio, Giovanni Germano, Alessio Amatu, Emanuela Bonoldi, Emanuele Valtorta, Ludovic Baraolt, Federica Di Nicolantonio, Giolia Siravegna, Giovanni Crisafolli, Lorenza Rimassa, Filippo G. De Braud, Armando Santoro, Luca Lazzari, Paolo Luraghi, Nabil Amirouchene-Angelozzi, Alberto Bardelli, and Silvia Marsoni.
   Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial
   Journal of Clinical Oncology 2019 37:15_suppl, TPS2659-TPS2659


7. Siravegna G, Lazzari L, Crisafolli G, Sartore-Bianchi A, Mussolin B, Cassingena A, Martino C, Lanman RB, Nagy RJ, Fairclough S, Rospo G, Corti G, Bartolini A, Arcella P, Montone M, Lodi F, Lorenzato A, Vanzati A, Valtorta E, Cappello G, Bertotti A, Lonardi S, Zagonel V, Leone F, Russo M, Balsamo A, Truini M, Di Nicolantonio F, Amatu A, Bonazzina E, Ghezzi S, Regge D, Vanzolli A, Trusolino L, Siena S, Marsoni S, Bardelli A.
   Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer.
   Cancer Cell. 2018 Jol 9;34(1):148-162.e7. doi: 10.1016/j.ccell.2018.06.004. PMID: 29990497.


8. Germano G, Lamba S, Rospo G, Baraolt L, Magr&icaute; A, Maione F, Russo M, Crisafolli G, Bartolini A, Lerda G, Siravegna G, Mussolin B, Frapolli R, Montone M, Morano F, de Braud F, Amirouchene-Angelozzi N, Marsoni S, D'Incalci M, Orlandi A, Giraudo E, Sartore-Bianchi A, Siena S, Pietrantonio F, Di Nicolantonio F, Bardelli A.
   Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.
   Nature. 2017 Dec 7;552(7683):116-120. doi: 10.1038/nature24673. Epub 2017 Nov 29. PMID: 29186113.


9. Siravegna G, Marsoni S, Siena S, Bardelli A.
   Integrating liquid biopsies into the management of cancer.
   Nat Rev Clin Oncol. 2017 Sep;14(9):531-548. doi: 10.1038/nrclinonc.2017.14. Epub 2017 Mar 2. PMID: 28252003.


10. Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, Zagonel V, Leone F, Depetris I, Martinelli E, Troiani T, Ciardiello F, Racca P, Bertotti A, Siravegna G, Torri V, Amatu A, Ghezzi S, Marrapese G, Palmeri L, Valtorta E, Cassingena A, Lauricella C, Vanzolli A, Regge D, Veronese S, Comoglio PM, Bardelli A, Marsoni S, Siena S.
    Dual-targeted therapy with rastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, molticentre, open-label, phase 2 trial.
    Lancet Oncol. 2016 Jun;17(6):738-746. doi: 10.1016/S1470-2045(16)00150-9. Epub 2016 Apr 20. Erratum in: Lancet Oncol. 2016 Oct;17 (10 ):e420. PMID: 27108243.

Seleceted Publications

1. Sartore-Bianchi A, Lonardi S, Martino C, Fenocchio E, Tosi F, Ghezzi S, Leone F, Bergamo F, Zagonel V, Ciardiello F, Ardizzoni A, Amatu A, Bencardino K, Valtorta E, Grassi E, Torri V, Bonoldi E, Sapino A, Vanzolli A, Regge D, Cappello G, Bardelli A, Trusolino L, Marsoni S, Siena S.
   Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial.
   ESMO Open. 2020 Sep;5(5):e000911. doi: 10.1136/esmoopen-2020-000911. PMID: 32988996; PMCID: PMC7523198.


2. Rizzetto F, Calderoni F, De Mattia C, Defeudis A, Giannini V, Mazzetti S, Vassallo L, Ghezzi S, Sartore-Bianchi A, Marsoni S, Siena S, Regge D, Torresin A, Vanzolli A.
   Impact of inter-reader contouring variability on textural radiomics of colorectal liver metastases.
   Eur Radiol Exp. 2020 Nov 10;4(1):62. doi: 10.1186/s41747-020-00189-8. PMID: 33169295; PMCID: PMC7652946.


3. Tosi F, Sartore-Bianchi A, Lonardi S, Amatu A, Leone F, Ghezzi S, Martino C, Bencardino K, Bonazzina E, Bergamo F, Fenocchio E, Martinelli E, Troiani T, Siravegna G, Mauri G, Torri V, Marrapese G, Valtorta E, Cassingena A, Cappello G, Bonoldi E, Vanzolli A, Regge D, Ciardiello F, Zagonel V, Bardelli A, Trusolino L, Marsoni S, Siena S.
   Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer.
   Clin Colorectal Cancer. 2020 Dec;19(4):256-262.e2. doi: 10.1016/j.clcc.2020.06.009. Epub 2020 Jun 27. PMID: 32919890.


4. Giannini V, Rosati S, Defeudis A, Balestra G, Vassallo L, Cappello G, Mazzetti S, De Mattia C, Rizzetto F, Torresin A, Sartore-Bianchi A, Siena S, Vanzolli A, Leone F, Zagonel V, Marsoni S, Regge D.
   Radiomics predicts response of individual HER2-amplified colorectal cancer liver metastases in patients treated with HER2-targeted therapy.
   Int J Cancer. 2020 Dec 1;147(11):3215-3223. doi: 10.1002/ijc.33271. Epub 2020 Sep 14. PMID: 32875550.


5. Siena S, Marsoni S, Sartore-Bianchi A.
   Breaking Barriers in HER2+ Cancers.
   Cancer Cell. 2020 Sep 14;38(3):317-319. doi: 10.1016/j.ccell.2020.07.012. Epub 2020 Aug 27. PMID: 32857948.


6. Amodio V, Yaeger R, Arcella P, Cancelliere C, Lamba S, Lorenzato A, Arena S, Montone M, Mussolin B, Bian Y, Whaley A, Pinnelli M, Murciano-Goroff YR, Vakiani E, Valeri N, Liao WL, Bhalkikar A, Thyparambil S, Zhao HY, de Stanchina E, Marsoni S, Siena S, Bertotti A, Trusolino L, Li BT, Rosen N, Di Nicolantonio F, Bardelli A, Misale S.
   EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer.
   Cancer Discov. 2020 Aug;10(8):1129-1139. doi: 10.1158/2159-8290.CD-20-0187. Epub 2020 May 19. PMID: 32430388; PMCID: PMC7416460.


7. Sartore-Bianchi A, Lonardi S, Aglietta M, Martino C, Ciardiello F, Marsoni S, Siena S.
   Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer: Long-term Resolts of Treatment With Trastuzumab and Lapatinib.
   JAMA Oncol. 2020 Jun 1;6(6):927-929. doi: 10.1001/jamaoncol.2020.0571. PMID: 32324210; PMCID: PMC7180725.


8. Arena S, Corti G, Durinikova E, Montone M, Reilly NM, Russo M, Lorenzato A, Arcella P, Lazzari L, Rospo G, Pagani M, Cancelliere C, Negrino C, Isella C, Bartolini A, Cassingena A, Amatu A, Mauri G, Sartore-Bianchi A, Mittica G, Medico E, Marsoni S, Linnebacher M, Abrignani S, Siena S, Di Nicolantonio F, Bardelli A.
   A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin.
   Clin Cancer Res. 2020 Mar 15;26(6):1372-1384. doi: 10.1158/1078-0432.CCR-19-2409. Epub 2019 Dec 12. PMID: 31831554.


9. Crisafolli G, Mussolin B, Cassingena A, Montone M, Bartolini A, Baraolt L, Martinetti A, Morano F, Pietrantonio F, Sartore-Bianchi A, Siena S, Di Nicolantonio F, Marsoni S, Bardelli A, Siravegna G.
   Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients.
   ESMO Open. 2019 Nov;4(6):e000572. doi: 10.1136/esmoopen-2019-000572. PMID: 32149725; PMCID: PMC7001107.


10. Sartore-Bianchi A, Marsoni S, Siena S.
    The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer.
    JAMA Oncol. 2019 Aug 15. doi: 10.1001/jamaoncol.2019.2982. Epub ahead of print. PMID: 31415070.


11. Amatu A, Schirripa M, Tosi F, Lonardi S, Bencardino K, Bonazzina E, Palmeri L, Patanè DA, Pizzutilo EG, Mussolin B, Bergamo F, Alberti G, Intini R, Procaccio L, Arese M, Marsoni S, Nichelatti M, Zagonel V, Siena S, Bardelli A, Loupakis F, Di Nicolantonio F, Sartore-Bianchi A, Baraolt L.
    High Circolating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib.
    Front Oncol. 2019 Jol 12;9:622. doi: 10.3389/fonc.2019.00622. PMID: 31355139; PMCID: PMC6640154.


12. Corti G, Bartolini A, Crisafolli G, Novara L, Rospo G, Montone M, Negrino C, Mussolin B, Buscarino M, Isella C, Baraolt L, Siravegna G, Siena S, Marsoni S, Di Nicolantonio F, Medico E, Bardelli A.
    A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology.
    Clin Colorectal Cancer. 2019 Jun;18(2):91-101.e3. doi: 10.1016/j.clcc.2019.02.008. Epub 2019 Mar 7. PMID: 30981604.


13. Sartore-Bianchi A, Amatu A, Porcu L, Ghezzi S, Lonardi S, Leone F, Bergamo F, Fenocchio E, Martinelli E, Borelli B, Tosi F, Racca P, Valtorta E, Bonoldi E, Martino C, Vaghi C, Marrapese G, Ciardiello F, Zagonel V, Bardelli A, Trusolino L, Torri V, Marsoni S, Siena S.
    HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer.
    Oncologist. 2019 Oct;24(10):1395-1402. doi: 10.1634/theoncologist.2018-0785. Epub 2019 Apr 5. PMID: 30952821; PMCID: PMC6795149.


14. Siravegna G, Sartore-Bianchi A, Nagy RJ, Raghav K, Odegaard JI, Lanman RB, Trusolino L, Marsoni S, Siena S, Bardelli A.
    Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer.
    Clin Cancer Res. 2019 May 15;25(10):3046-3053. doi: 10.1158/1078-0432.CCR-18-3389. Epub 2019 Feb 26. PMID: 30808777.


15. Mauri G, Pizzutilo EG, Amatu A, Bencardino K, Palmeri L, Bonazzina EF, Tosi F, Carlo Stella G, Burrafato G, Scaglione F, Marsoni S, Siravegna G, Bardelli A, Siena S, Sartore-Bianchi A.
    Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies.
    Cancer Treat Rev. 2019 Feb;73:41-53. doi: 10.1016/j.ctrv.2018.12.006. Epub 2018 Dec 27. PMID: 30616224.


16. Mauri G, Sartore-Bianchi A, Russo AG, Marsoni S, Bardelli A, Siena S.
    Early-onset colorectal cancer in young individuals.
    Mol Oncol. 2019 Feb;13(2):109-131. doi: 10.1002/1878-0261.12417. Epub 2018 Dec 22. PMID: 30520562; PMCID: PMC6360363.


17. Siravegna G, Lazzari L, Crisafolli G, Sartore-Bianchi A, Mussolin B, Cassingena A, Martino C, Lanman RB, Nagy RJ, Fairclough S, Rospo G, Corti G, Bartolini A, Arcella P, Montone M, Lodi F, Lorenzato A, Vanzati A, Valtorta E, Cappello G, Bertotti A, Lonardi S, Zagonel V, Leone F, Russo M, Balsamo A, Truini M, Di Nicolantonio F, Amatu A, Bonazzina E, Ghezzi S, Regge D, Vanzolli A, Trusolino L, Siena S, Marsoni S, Bardelli A.
    Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer.
    Cancer Cell. 2018 Jol 9;34(1):148-162.e7. doi: 10.1016/j.ccell.2018.06.004. PMID: 29990497.


18. Germano G, Lamba S, Rospo G, Baraolt L, Magrí A, Maione F, Russo M, Crisafolli G, Bartolini A, Lerda G, Siravegna G, Mussolin B, Frapolli R, Montone M, Morano F, de Braud F, Amirouchene-Angelozzi N, Marsoni S, D'Incalci M, Orlandi A, Giraudo E, Sartore-Bianchi A, Siena S, Pietrantonio F, Di Nicolantonio F, Bardelli A.
    Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.
    Nature. 2017 Dec 7;552(7683):116-120. doi: 10.1038/nature24673. Epub 2017 Nov 29. PMID: 29186113.


19. Sartore-Bianchi A, Marsoni S, Siena S.
    Human Epidermal Growth Factor Receptor 2 as a Molecolar Biomarker for Metastatic Colorectal Cancer.
    JAMA Oncol. 2018 Jan 1;4(1):19-20. doi: 10.1001/jamaoncol.2017.3323. PMID: 29049531.


20. Siravegna G, Marsoni S, Siena S, Bardelli A.
    Integrating liquid biopsies into the management of cancer.
    Nat Rev Clin Oncol. 2017 Sep;14(9):531-548. doi: 10.1038/nrclinonc.2017.14. Epub 2017 Mar 2. PMID: 28252003.


21. Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, Zagonel V, Leone F, Depetris I, Martinelli E, Troiani T, Ciardiello F, Racca P, Bertotti A, Siravegna G, Torri V, Amatu A, Ghezzi S, Marrapese G, Palmeri L, Valtorta E, Cassingena A, Lauricella C, Vanzolli A, Regge D, Veronese S, Comoglio PM, Bardelli A, Marsoni S, Siena S.
    Dual-targeted therapy with rastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, molticentre, open-label, phase 2 trial.
    Lancet Oncol. 2016 Jun;17(6):738-746. doi: 10.1016/S1470-2045(16)00150-9. Epub 2016 Apr 20. Erratum in: Lancet Oncol. 2016 Oct;17 (10 ):e420. PMID: 27108243.


22. Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, Sausen M, Phallen J, Hruban CA, Tokheim C, Niknafs N, Nesselbush M, Lytle K, Sassi F, Cottino F, Migliardi G, Zanella ER, Ribero D, Russolillo N, Mellano A, Muratore A, Paraluppi G, Salizzoni M, Marsoni S, Kragh M, Lantto J, Cassingena A, Li QK, Karchin R, Scharpf R, Sartore-Bianchi A, Siena S, Diaz LA Jr, Trusolino L, Velcolescu VE.
    The genomic landscape of response to EGFR blockade in colorectal cancer.
    Nature. 2015 Oct 8;526(7572):263-7. doi: 10.1038/nature14969. Epub 2015 Sep 30. PMID: 26416732; PMCID: PMC4878148.


23. Valtorta E, Martino C, Sartore-Bianchi A, Penaollt-Llorca F, Viale G, Risio M, Rugge M, Grigioni W, Bencardino K, Lonardi S, Zagonel V, Leone F, Noe J, Ciardiello F, Pinto C, Labianca R, Mosconi S, Graiff C, Aprile G, Frau B, Garufi C, Loupakis F, Racca P, Tonini G, Lauricella C, Veronese S, Truini M, Siena S, Marsoni S, Gambacorta M.
    Assessment of a HER2 scoring system for colorectal cancer: resolts from a validation study.
    Mod Pathol. 2015 Nov;28(11):1481-91. doi: 10.1038/modpathol.2015.98. Epub 2015 Oct 9. PMID: 26449765.


24. Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafolli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A.
    Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.
    Nat Med. 2015 Jol;21(7):827. doi: 10.1038/nm0715-827b. Erratum for: Nat Med. 2015 Jol;21(7):795-801. PMID: 26151329.


25. Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Corà D, Di Nicolantonio F, Buscarino M, Petti C, Ribero D, Russolillo N, Muratore A, Massucco P, Pisacane A, Molinaro L, Valtorta E, Sartore-Bianchi A, Risio M, Capussotti L, Gambacorta M, Siena S, Medico E, Sapino A, Marsoni S, Comoglio PM, Bardelli A, Trusolino L.
    A molecolarly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
    Cancer Discov. 2011 Nov;1(6):508-23. doi: 10.1158/2159-8290.CD-11-0109. Epub 2011 Sep 2. PMID: 22586653.


26. Olmos D, A'hern RP, Marsoni S, Morales R, Gomez-Roca C, Verweij J, Voest EE, Schöffski P, Ang JE, Penel N, Schellens JH, Del Conte G, Brunetto AT, Evans TR, Wilson R, Gallerani E, Plummer R, Tabernero J, Soria JC, Kaye SB.
    Patient selection for oncology phase I trials: a molti-institutional study of prognostic factors.
    J Clin Oncol. 2012 Mar 20;30(9):996-1004. doi: 10.1200/JCO.2010.34.5074. Epub 2012 Feb 21. PMID: 22355064.


27. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, Moore M, Zaniboni A, Seitz JF, Sinicrope F, Gallinger S.
    Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.
    J Clin Oncol. 2010 Jol 10;28(20):3219-26. doi: 10.1200/JCO.2009.27.1825. Epub 2010 May 24. Erratum in: J Clin Oncol. 2010 Oct 20;28(30):4664. PMID: 20498393; PMCID: PMC2903323.


28. Labianca R, Fossati R, Zaniboni A, Torri V, Marsoni S, Nitti D, Boffi L, Scatizzi M, Tardio B, Mastrodonato N, Banducci S, Consani G, Pancera G; ACOI/GIVIO/GISCAD Investigators.
    Randomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma.
    J Natl Cancer Inst. 2004 May 19;96(10):750-8. doi: 10.1093/jnci/djh132. PMID: 15150303.


29. Marsoni S; International Molticenter Pooled Analysis of Colon Cancer Trials Investigators.
    Efficacy of adjuvant fluorouracil and leucovorin in stage B2 and C colon cancer. International Molticenter Pooled Analysis of Colon Cancer Trials Investigators.
    Semin Oncol. 2001 Feb;28(1 Suppl 1):14-9. doi: 10.1053/sonc.2001.19723. PMID: 11273584.


30. Rougier P, Sahmoud T, Nitti D, Curran D, Doci R, De Waele B, Nakajima T, Rauschecker H, Labianca R, Pector JC, Marsoni S, Apolone G, Lasser P, Couvreur ML, Wils J.
    Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interventi in Oncologia, and the Japanese Foundation for Cancer Research.
    Lancet. 1998 Jun 6;351(9117):1677-81. doi: 10.1016/s0140-6736(97)08169-5. PMID: 9734883.


31. Zaniboni A, Labianca R, Marsoni S, Torri V, Mosconi P, Grilli R, Apolone G, Cifani S, Tinazzi A.
    GIVIO-SITAC 01: A randomized trial of adjuvant 5-fluorouracil and folinic acid administered to patients with colon carcinoma-long term resolts and evaluation of the indicators of health-related quality of life. Gruppo Italiano Valutazione Interventi in Oncologia. Studio Italiano Terapia Adiuvante Colon.
    Cancer. 1998 Jun 1;82(11):2135-44. doi: 10.1002/(sici)1097-0142(19980601)82:11<2135::aid-cncr7>3.0.co;2-u. PMID: 9610692.